As a leading company for contract development and manufacturing, our LPBN segment is recognized for its reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and extensive experience.
Our vision is to enable our customers to meet some of the greatest challenges in patient treatment. We cover a wide range of services within the biopharma industry. Our broad capabilities span biologics, small molecules (including highly potent active pharmaceutical ingredients such as cytotoxins), bioconjugates and cell and gene technologies. We support projects from research, discovery and pre-clinical stages, through clinical trials to commercialization and our expertise extends across both drug substance and drug product.
The LPBN segment includes the following offerings:
Development and Manufacturing Sites
Employees (Full-Time Equivalent)
Pre-clinical and Clinical Small 1 and Large 2 Molecules
Commercial Small 1 and Large 2 Molecules
Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering
Including mammalian, microbial, cell & gene therapy products and bioconjugates (applied protein services and drug product services are included for pre-clinical and clinical molecules only)
Chief Operating Officer (COO) Pharma & Biotech
In 2020, our Technical Operations community has shown strong progress on execution performance, which has enabled us to successfully deliver more than 1,000 customer projects across 37 sites worldwide. Moreover, we have commenced operations on a significant number of organic growth projects, supported by a steep hiring increase. Throughout the year, we have onboarded around 2,000 new operations employees in both our base business and strategic growth investments.
Across the teams, we have continuously worked on managing and mitigating the challenges arising from the COVID-19 pandemic to ensure we could maintain supply to our customers. For example, digital solutions were implemented to connect employees, customers and other stakeholders in times of social distancing and restricted travel. These included remote audits and compliance assessments, remote maintenance and virtual training, as well as virtual site tours. We also implemented a home office approach for around 30% of our employee community.
While maintaining our base operations throughout the year, we have established new facilities to upscale worldwide production of vaccines against COVID-19. Being in a position to actively support the fight against the pandemic is a privilege and underlines our teams’ outstanding determination and expertise in delivering innovative technologies against highly ambitious targets.
In 2020, the Lonza Pharma Biotech & Nutrition (LPBN) segment achieved 12.2%1 sales growth and a 32.1% CORE EBITDA margin. We saw a strong performance across our businesses, with Biologics remaining a primary driver of growth. The LPBN segment demonstrated resilience to the impacts of COVID-19. Facilities remained open and supply chains were managed to ensure business continuity. The business worked diligently to expand service offerings to customers while investing in production capacity in response to continued demand.
Sales growth at constant exchange rate (CER)
|Million CHF||2020||2019||Change in %|
|Margin in %||32.1||32.9|
|CORE result from operating activities (EBIT)||1,172||1,125||4.2|
|Margin in %||26.2||27.0|